secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-174947
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO amends AbbVie deal; restructures $200M milestones, starts DR pivotal; Q2 net loss $70.9M
--------------------------------------------------------------------------------

- Amendment to AbbVie collaboration: $100M milestone upon first pt dosed in Phase IIb/III DR trial, additional $100M upon first pt in Phase III.
- REGENXBIO to pay costs for Phase IIb of that trial; AbbVie to fund new Phase III wAMD study (ACHIEVE).
- Q2 net loss $70.9M ($1.38/share) vs $53.0M loss year ago; revenue $21.4M, down from $22.3M.
- Cash $363.6M at June 30, 2025; expects to fund operations into early 2027.
- RGX-202 Duchenne pivotal enrollment accelerated, to complete Oct 2025; topline data 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/0001193125-25-174947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer